Oral lichen planus: A look from diagnosis to treatment. by Córdova, Pablo et al.
Introduction.
Oral lichen planus (OLP) is a mucocutaneous disease
which can alter the skin, oral mucosa and other mucous
membranes. It affects approximately one to two percent
of  the population, mainly women, and it occurs most
frequently during the fifth and sixth decades of  life.
Usually, oral lesions appear before skin lesions and,
sometimes, they expose themselves only in the oral
mucosa. In the mouth, the most affected area is the
buccal mucosa, although it can present itself  on the
tongue, gums and/or palate as well1-7.
The course is chronic with frequent recurrences.
Diagnosis is based on clinic and histology, but tech-
niques such as direct immunofluorescence (DIF) can
provide a valuable additional criterion. There is no fully
effective treatment1-8.
Etiology and pathogenesis.
Today, it is considered a disease of  obscure
etiology, although various triggers are proposed.
Besides, there is a considerable controversy about
OLP pathogenesis2- 9. Current evidence presents
multifactorial pathogenesis of  various immune
mechanisms2, 3, 10-13:
1. Antigen - specific immune response: CD8+
cytotoxic cells are activated in OLP by major histocom-
patibility complex class I and II molecules when antigens
are presented.
2. The proposed mechanisms involved in non-
specific immune response are mast cell degranulation
and marked matrix metalloproteinases activation.
3. Another hypothesis is the autoimmune response.
It is supported by various OLP characteristics such as
chronicity, adult onset, association with other autoim-
mune diseases, female predilection, lack of  TGF-
ß1expression, overexpression of  heat shock proteins,
keratinocytes apoptosis and Langerhans cell maturation.
Among others, these factors have been proposed
as causative agents: genetic component, trauma, drugs,
both viral and bacterial infectious agents, food allergy,
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Abstract: Oral lichen planus (OLP) is a chronic mucocutaneous disease of  unknown
etiology. Its pathogenesis is multifactorial and it may affect the oral mucosa, skin and
other mucous membranes.  Diagnosis is based on clinic and histopathology; direct
immunofluorescence techniques can also be of use. It affects about one to two percent
of  the population, mainly women between the fifth and sixth decades of  life. In the
mouth, the most affected area is the buccal mucosa, followed by the gums, tongue
and/or palate. Its three most representative clinical forms are reticular, erythematous
and erosive; evolution depends on the type it is. Lesion treatment is determined by the
clinical form and, since no fully effective treatment has been found yet, it is directed
towards controlling the disease. The treatment of  choice involves topical or systemic
corticosteroids, but other drugs may also be used.The aim of  this paper is to gather
current and relevant information about oral lichen planus: its pathogenesis, diagnosis,
treatment and management.
Keywords: Oral Lichen Planus, Clinical/Histopathology Diagnosis, Corticosteroids,
Neoplasms.
Liquen plano oral: Una mirada desde el diagnóstico al
tratamiento.
Resumen: El liquen plano oral (LPO) es una enfermedad crónica mucocutánea de
etiología poco conocida, cuya patogénesis es multifactorial, y  puede afectar a la mucosa
oral, piel y otras mucosas. El diagnóstico está basado en la clínica y la histopatología.
Además, técnicas como la inmunofluorescencia directa pueden contribuir al diagnóstico
de la enfermedad. Afecta del 1 al 2% de la población, principalmente mujeres, entre
la quinta y sexta décadas de la vida. En boca, la zona más afectada es la mucosa yugal,
seguido de encías, lengua y/o paladar. Las tres formas clínicas más representativas son:
reticular, eritematosa y erosiva, cuya evolución varía según el tipo. El tratamiento de
las lesiones depende de la forma clínica y está dirigido hacia un control de la enfermedad,
ya que en la actualidad no se conoce un tratamiento del todo efectivo. El tratamiento
de elección es la utilización de corticoides, en forma tópica o sistémica, aunque otros
fármacos  también pueden ser utilizados para el manejo de la enfermedad. El objetivo
del presente artículo es recopilar información actualizada y relevante del liquen plano
oral en su etiopatogenia, diagnóstico, tratamiento y manejo de la enfermedad.
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autoimmunity, stress, immunodeficiency, dental materials
and diabetes.
Some authors have described its relationship with
hepatitis C, however, this aspect has generated discrep-
ancies. In this sense, it has been possible to describe
such association in some geographic areas while, in
others, evidence has not been found1,3,11,12,14-16.
There is a close relationship between OLP and
psychosomatic disorders, mainly anxiety and stress.
Some researchers suggest that the combination of
psychiatric and OLP treatment can be effective in
reducing the lesion size or even their remission in
patients with OLP1-3, 12-17.
Diagnosis and classification.
Six clinical forms of  OLP have been proposed:
white striations (reticular), white plaques, white papules,
erosive, atrophic and bullous. For this review, the three
most representative clinical forms were considered:
reticular, erythematous and erosive.
The reticular form is usually presented with a
symmetrical character in both mucous membrane areas,
especially in buccal mucosa, and few symptoms. It is
common to observe the erythematous type in the jugal
mucosa, tongue and/or gums; the latter often in the
form of  desquamative gingivitis. The erosive form is
painful; on the contrary, erythematous causes discomfort
but no pain, manifesting itself  mainly in the buccal
mucosa and dorsal tongue. It is part of  the clinical
criteria to find reticular lesions peripherally to the
atrophic-erosive lesions1, 7, 9, 18-20.
In patients with lichen planus, diagnosis should
always be made by combining clinical findings with
histopathology18. A DIF study, which usually gives
positive results in basement membrane with fibrinogen,
can also be performed. Biopsy is necessary because it
allows confirming clinical and differential diagnosis
with other lesions such as lichenoid reaction, lupus,
pemphigus, pemphigoid and leukoplakia, among others.
There are a series of  lesions which are both clinically
and histologically similar to idiopathic lichen planus,
the so-called "lichenoid reactions".19 These include lichenoid
lesions by contact, drug-induced lichenoid reactions,
and lichenoid reactions associated to graft versus host
reaction18. Often, clinical and histology alone are not
able to differentiate an idiopathic lichen planus from
a lichenoid reaction20-22.
Clinical criteria comprise presence of  bilateral
symmetrical lesions and white reticular lesions. Lesions
may be atrophic, erosive, blistering or take the form
of  plaque which appears along with reticular lesions
in a specific area of  the oral cavity. When both criteria
are met, it is considered a typical lichen planus. Lesions
simulating lichen planus, but not meeting the previous
criteria, are considered clinically compatible with lichen
planus.
Histological criteria include: a band of  lymphocytic
inflammatory infiltrate in the subepithelial connective
tissue, liquefaction degeneration of  the basement
membrane and the absence of  epithelial dysplasia. If
these three criteria are met, the injury is considered a
typical lichen planus from a histopathological point of
view. Those not meeting any of  the histopathological
criteria are considered histologically consistent with
lichen planus.1, 22, 23
By contrast, lichenoid reaction includes patients with
typical lichen planus clinically but not histologically, those
with histological level but not clinical, and the ones who
are clinically and histologically compatible.22, 23
Malignant potential.
One of  the potential complications of  OLP is
the chance of  malignant transforming. However,
this phenomenon is still the subject of  much
controversy24-27. Literature contains a growing number
of  clinical series in relation to the malignant potential
of  OLP, although some authors question the current
evidence28-30.
Since 1910, when the first case of  oral squamous
cell carcinoma (OSCC) in a patient with OLP was
reported, these published series have displayed a ma-
lignancy rate of  0 to 12.5%22, 31, 32.
In literature reviews, comparisons are difficult
because of  differences in the criteria used for OLP
diagnose, lack of  information about oral exposure
to carcinogenic agents, variability in the selection,
lesion identification and location, and differences
in monitoring patients. Nevertheless, most studies
indicate that OLP patients may develop oral cancer,
increasing the risk of  incidence (10 times) compared
to general population24, 33, 34.
Furthermore, oncogenesis has been associated with
other risk factors which should also be taken into
account. Nowadays, not only tobacco and alcohol but
also Candida infection and the possible role of  different
oncogenic virus like human papilloma virus (HPV)
and Epstein Barr virus (EBV) have to be considered.
Also, the possible influence of  nutrition, genetics and
heredity, and immune suppression induced by certain
treatments used for OLP should be taken into
consideration27, 32, 33, 35.
In particular, erythematous and erosive forms of
OLP are most likely considered to malignify, although
the evidence for this hypothesis is weak. From different
intraoral sites, tongue seems to be the preferred place
for malignant transformation, according to observations
by Tizeira Lanfranchi et al.31 Nevertheless, Mignogna
et al.25 reported an increase in the frequency of  carci-
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nomas in the midline palate, gums and lips; and, con-
versely, Rajentheran et al.36 indicated the buccal mucosa
as the most affected area.
Considering patient’s sex and age, there seems to
be agreement o the fact that the risk is higher in women
between the sixth and seventh decades of  life27-31.
It was found that OLP-OSCC subjects are more likely
to develop a second or third oral cancer, and have lymph
node metastases, compared to OSCC-only control subjects.
This observation would be consistent with a field cancer-
ization phenomenon.26 Therefore, clinical follow-up for
these patients is essential in order to establish an early
malignant transformation diagnosis3, 25-26.
Van der Meij et al. considered the following criteria
for lichen planus malignant transformation22:
A. It typically requires clinical lichen planus diagnosis
with histopathology including at least two of  the
following four signs:
• Hyperkeratosis or parakeratosis.
• Serrated-shape interpapillar gingival crest.
• Subepithelial infiltration band.
• Hydropic degeneration of  the basal layer.
B. History and monitoring.
• Clinical and histological data showing the trans-
formation must be properly documented (both previous
lesions and when malignant transformation occurred).
• Clinical data such as age, sex and lesion location
must be registered.
• At least, two year follow-up.
C. Exposure to tobacco.
• Those patients who smoke and have a carcinoma,
attributed to tobacco, should be discarded.
Corticosteroids and other treatments.
The main goal of  any treatment is OLP symptomatic
control. In general, patients with reticular OLP lesions
and other asymptomatic lesions do not require active
t reatment11, 20-21.
It is important to eliminate potential triggers and
irritants such as dental malocclusion or fractured carious
teeth, poorly fitting dentures; alcohol and tobacco
consumption should be identified and avoid-
ed/eliminated whenever possible3, 37. Good oral hygiene,
alongside with the use of  chlorhexidine mouthwashes
and plaque reduction, may have beneficial effects on
lesions; therefore, they should also be indicated3, 38-39.
As OLP is a chronic disease, patient history, psy-
chological status, treatment compliance and drug
interaction should be considered when evaluating any
treatment modality17, 37-39.
There are various treatments which have been
proposed to improve symptomatic OLP evolution, but
none exists to cure the disease. In particular, some
treatment modalities suggest lichenoid lesions induction,
and do not improve their previous state. Topical treat-
ment is generally preferred because it has fewer adverse
effects. However, systemic agents may be necessary if
lesions are generalized, they occur essentially in the
skin or other non-oral mucosa1-40.
Most published studies consider topical corticos-
teroids as the most useful drug for OLP treatment. A
positive response to medium-potency corticosteroid
treatment, such as acetate triamcinolone 0.1%, powerful
fluorinated steroids as fluocinolone acetonide 0.05%
and 0.1%, and more high-potency halogenated corti-
costeroids, like clobetasol propionate 0.05%, has been
reported in most treated patients1,11, 21,41.
In particular, clobetasol propionate appears to be
the most effective topical steroid, reporting a high
remission rate (56-75%) of  OLP signs and symptoms.
Moreover, clobetasol has shown to be more effective
than triamcinolone acetate and fluocinolone in com-
parative studies37.
The main problem when using topical corticoster-
oids is for adhering them to the mucosa for a sufficient
period of  time11. Adhesive pastes such as sodium
carboxymethylcellulose (Orabase), hydroxyethyl cellulose
and special drug delivery systems such as lipid laden
microspheres have been suggested for this purpose42.
Aditionally, adrenal suppression is not found in the
long term, even with oral application of  topical corti-
costeroids such as triamcinolone acetonide, fluocinolone
and clobetasol propionate41-43-44.
Pseudomembranous candidiasis is the only common
side-effect of  treatment with topical corticosteroids.
This can be prevented by using antifungals such as
miconazole gel4-16 or chlorhexidine rinses42. Topical
steroids can be applied using splints where there are
gingival lesions45.
Prolonged use of  these drugs can sometimes result
in a decrease in biological effectiveness (tachyphylaxis)11.
This can be avoided by using a high-potency steroid
(i.e. clobetasol) at first and then a moderate corticos-
teroid (i.e. triamcinolone) for maintenance therapy20.
Systemic corticosteroids are usually reserved for
cases where OLP is widespread, involving the skin,
genitals, esophagus or scalp. Prednisone doses of  40
to 80 mg per day are usually enough to achieve response
both when taken for short periods of  time (five-seven
days) and then abruptly withdrawn, or 5-10 mg dose
per day which is gradually reduced over two to four
weeks11, 20, 39, 41-46.
Immunomodulatory agents, such as calcineurin
inhibitors (cyclosporine, tacrolimus, sirolimus or tac-
rolimus) or retinoids, may be beneficial, especially if
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the lesions are resistant to the highest- potency steroids.
Cyclosporin has been used as a mouthwash or
adhesive bases, but it is expensive, not always effective,
and less potent than topical clobetasol to induce OLP
clinical improvement13, 47, 48.
Tacrolimus is 10-100 times more potent than cy-
closporine.11 Several studies have documented this
agent efficacy and safety (at a concentration of  0.03%
to 0.1%) in the erosive OLP evolution13, 49, 50, 51. However,
tacrolimus therapeutic levels in OLP patients have
been associated with oral absorption after topical
application, leading to systemic side effects53,54. In
addition, OLP relapses after tacrolimus discontinuation
are common13,50.
Pimecrolimus is another calcineurin inhibitor
used in OLP treatment. Its action is similar to
tacrolimus, but it has no effect on the Langerhans
cells. Pimecrolimus immunosuppressive capacity is
weaker than cyclosporin or tacrolimus, and it has
lower permeability through the skin compared to
topical steroids and tacrolimus13,53.
However, the FDA issued a "black box" warning
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Table 1. Summary of  pharmacological, non-pharmacological and auxiliary therapies and main indications for treating oral lichen planus
on the use of  tacrolimus and pimecrolimus due to an
increased theoretical risk of  cancer (squamous cell
carcinoma and lymphoma) in patients treated with
tacrolimus/pimecrolimus for psoriasis3 ,11 ,54 ,55.
Topical Rapamycin (sirolimus) has been recently
proposed in refractory erosive OLP cases, because it
has immunosuppressive properties and is a tumoral
inhibitor, thus decreasing LPO malignancy risk13,56.
Topical retinoids such as tretinoin, isotretinoin and
fenretinide, often cause side effects and are generally
less effective than topical corticosteroids. Moreover,
their use should be limited to topical and second-line
treatments should be considered1,11,57.
Various systemic immunosuppressive agents have
been used for treating OLP. Biological agents as basil-
iximab, etanercept, efalizumab, and alefacept have been
proposed for OLP treatment. However, due to the low
cost/benefit ratio, its use is limited to patients with
severe disease manifestations or those who have failed
with traditional treatments such as topical corticosteroids
and calcineurin inhibitors11, 58-60.
As immunosuppressive drugs used for OLP have
not been developed for oral diseases, there is need for
appropriate studies to determine their efficacy and
optimal dose, treatment duration and safety to avoid
side effects61.
Non-pharmacologic methods, such as photodynam-
ic therapy (PDT), ultraviolet longwave radiation (PUVA),
and surgical treatment with CO2 laser have been
proposed, especially for patients with recurrences after
more conventional therapies. Yet, their effectiveness
has not been tested and, apparently, the surgery also
induces OLP11, 59, 60, 62-64.
Table 1 shows the main treatments for OLP.
Conclusion.
Lichen planus is a chronic mucocutaneous disease
of  multifactorial etiology and pathogenesis. OLP is
considered a potentially malignant lesion, so lesion
monitoring must be periodic even in asymptomatic
patients, and symptomatic ones should be treated.
Corticosteroids are considered as first-line treatments
since their topical form has better benefits and fewer
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